Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
|
|
Sexually Transmitted Infections Vol. 82: P. 397-402 (10..06) - Thursday, December 28, 2006
S.C. Thomsen; W. Ombidi; C. Toroitich-Ruto; E.L. Wong; H.O. Tucker; R. Homan; N. Kingola; S. Luchters
Participants were interviewed about their sexual behavior every two months for a total of seven interviews. After the third interview, they were introduced to female condoms. The researchers collected cost data and calculated the cost and cost-effectiveness of adding the female condom to the existing program.
The addition of the female condom to the HIV prevention program "led to small, but significant, increases in consistent condom use with all sexual partners," the researchers found. However, substitution for male condoms was high. At the program level, the cost per additional consistent female condom user was estimated at $2,160 (95 percent confidence interval: 1,338 to 11,179).
The results suggest the female condom "has some potential for reducing unprotected sex among sex workers," the authors concluded. "However, given its high cost, and the marginal improvements seen here, governments should limit promotion of the female condom in populations that are already successfully using the male condom." The investigators called for more research to find effective ways of "encouraging sex workers to practise safer sex with their boyfriends."
061228
AD062513
Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.